SecBot SecBot
Biotech Drug Report Generated Nov 8, 2026

KER-206

KROS·Keros Therapeutics, Inc.
NEUTRAL
Drug Impact Rating2/10
Trial phase
Nonclinical / Preclinical
Time to market
KER-206 is at the nonclinical stage. Assuming successful IND-enabling studies, Phase 1 initiation would be at least 12-18 months away. Commercialization, if successful, would be many years away (likely 2030s).
Why 2/10
KER-206 is a nonclinical (preclinical) program that was just nominated for further investigation in Q3 2026. There is no scheduled PDUFA date, pivotal readout, or other hard binary catalyst within the next 12 months. The earliest meaningful catalyst would be an IND filing or Phase 1 initiation, which is likely more than a year away.
Actionable Insight NEUTRAL

KER-206 is a preclinical asset with no near-term catalysts. The next meaningful update would likely come when Keros announces plans to file an IND or initiate first-in-human studies, which is probably 12+ months away. For KROS investors, the more immediate value drivers are the Phase 2 rinvatercept data in DMD expected in H1 2027 and Takeda's Phase 3 progress with elritercept.

Price Chart

Loading chart...

Executive Summary

KER-206 is a nonclinical (preclinical) ligand trap drug candidate from Keros Therapeutics (NASDAQ: KROS), designed to treat osteoporosis by promoting bone remodeling. It was nominated for further investigation in Q3 2026, with the company reporting that it showed reversal of bone loss in a mouse model of osteoporosis. KER-206 is at the very earliest stage of development, with no clinical trials initiated, no IND filed, and no near-term catalysts. It represents a small, early-stage program within Keros' broader pipeline, which is led by elritercept (KER-050, licensed to Takeda in Phase 3) and rinvatercept (KER-065, in Phase 2 for Duchenne muscular dystrophy).

How It Works

KER-206 is a ligand trap, a type of biologic drug designed to bind to and neutralize specific signaling proteins in the TGF-beta family that regulate bone remodeling. By blocking these signals, it aims to shift the balance toward bone formation, potentially reversing bone loss in conditions like osteoporosis. It is administered as an injectable protein therapy, similar to Keros' other pipeline drugs.

Trial Status

KER-206 was nominated as a development candidate in Q3 2026. It has demonstrated reversal of bone loss in a mouse model of osteoporosis. No human trials have been initiated, and no IND has been filed. The program is in the nonclinical (preclinical) stage.

The Two-Sided Case

▲ Bull Case4
KER-206 showed reversal of bone loss in a mouse model of osteoporosis, suggesting potential as a novel anabolic (bone-building) therapy in a large market.
Keros has expertise in TGF-beta family ligand traps, having already advanced KER-050 (elritercept) into Phase 3 via a Takeda partnership and KER-065 (rinvatercept) into Phase 2.
The company has $259.5M in cash as of September 2026, providing runway into H2 2028 to advance KER-206 toward the clinic.
Analyst consensus is bullish on KROS overall, with 9 Buy/Strong Buy ratings vs 4 Hold and 0 Sell, and a mean price target of $19.83 (more than 2x the current $9.36 price).
▼ Bear Case4
KER-206 is at the nonclinical stage, meaning it has not yet entered human trials and faces a high probability of failure before ever reaching the clinic.
Osteoporosis is a highly competitive market with established therapies (bisphosphonates, denosumab, romosozumab) and many novel entrants, making differentiation difficult for an early-stage ligand trap.
Keros has no approved products and is burning cash (core operating loss of ~$27M in Q3 2026); KER-206 will require significant additional investment before generating any value.
The stock trades near its 52-week low of $9.26, and the company's cash runway only extends into H2 2028, potentially requiring dilutive financing.

Upcoming Catalysts

  • No near-term catalysts for KER-206 specifically. The next milestone would be IND-enabling studies and potential IND filing, likely 12+ months away.

Source Filing

The SecBot filing or press-release report that triggered this drug report:

Keros Therapeutics, Inc. 8-K KROS ·Originating report

Sources · 5

Hover a chip for the title
1 globenewswire.com2 sec.gov3 sec.gov4 markets.businessinsider.com5 marketscreener.com